MSB 0.71% $1.78 mesoblast limited

Cell Therapy News/Articles, page-360

  1. 844 Posts.
    lightbulb Created with Sketch. 307
    Spinal fusion uses bone grafts to fuse 2 or more vertebrae together when the disc between them degenerates. It usually needs various supplements to get the grafts to fuse - and at one stage stem cells themselves were a candidate to enhance fusion.

    What about the P3 ready MPC-25-Osteo, its' actual intention is to replace hip bone grafts for spinal fusion.

    "A Phase 2 study has been completed where MPC-25-Osteo was implanted into the intervertebral disc space of 24 patients undergoing 1 or 2-level lumbar interbody fusion via posterior procedures. Click here for trial results."

    http://www.mesoblast.com/product-candidates/spine-orthopedic-disorders/spinal-fusion

    The stage the candidate from Ankasa Regenerative Therapeutics is at seems to be coming up for P2.
    https://www.cirm.ca.gov/our-progress/awards/autologous-somatic-stem-cell-therapy-treatment-osteonecrosis
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.78
Change
0.013(0.71%)
Mkt cap ! $1.113B
Open High Low Value Volume
$1.79 $1.81 $1.77 $2.400M 1.345M

Buyers (Bids)

No. Vol. Price($)
13 10093 $1.78
 

Sellers (Offers)

Price($) Vol. No.
$1.79 13629 11
View Market Depth
Last trade - 12.39pm 02/12/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.